Recently, CD47 blockade (Hu5F9-G4 or magrolimab), which is a macrophage checkpoint inhibitor that induces macrophage-mediated tumor killing, combined with rituximab [38] showed potential efficacy in patients with relapsed or refractory FL. This evidence concerns the gene CD47 and neoplasm.